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Abstract: Bengazoles A–G from the marine sponge Jaspis sp. exhibit potent in vitro antifungal activity
against Candida spp. and other pathogenic fungi. The mechanism of action (MOA) of bengazole A
was explored in Candida albicans under both liquid culture and surface culture on Mueller-Hinton
agar. Pronounced dose-dependent synergistic antifungal activity was observed with bengazole
A in the presence of bengamide A, which is also a natural product from Jaspis sp. The MOA of
bengazole A was further explored by monitoring the sterol composition of C. albicans in the presence
of sub-lethal concentrations of bengazole A. The GCMS of solvent extracts prepared from liquid
cultures of C. albicans in the presence of clotrimazole—a clinically approved azole antifungal drug that
suppresses ergosterol biosynthesis by the inhibition of 14α-demethylase—showed reduced cellular
ergosterol content and increased concentrations of lanosterol and 24-methylenedihydrolanosterol
(a shunt metabolite of ergosterol biosynthesis). No change in relative sterol composition was observed
when C. albicans was cultured with bengazole A. These results eliminate an azole-like MOA for the
bengazoles, and suggest that another as-yet unidentified mechanism is operative.
Keywords: antifungal; alkaloid; synergism; Candida albicans
1. Introduction
The tropical sponge, Jaspis cf. coriacea, is the original source of two classes of unrelated natural
products: bengazoles and bengamides, (Figure 1) first reported by Crews et al. [1]. Bengamides
A (1a) [2,3] and B (1b) and related analogs are potent nanomolar inhibitors of cancer cell growth,
with selective in vitro activity in the NCI 60 cell line panel [4]. Compound 1a reduced MDA-MB-435
breast carcinoma in an in vivo rat zenograft model [4]. The unique cytotoxicity of bengamides has been
attributed to the inhibition of methionine aminopeptidases [5,6]. A synthetic analog of 1a, LAF-389 [7],
was advanced to phase I clinical trials before discontinuation of the study due to intolerable toxicity [8].
Candida species, including C. albicans, C. krusei, and C. glabrata, are responsible for 8–10% of
hospital-acquired (nosocomial) systemic mycoses, and are associated with mortality rates of up to 71%.
The rising rate of fatal candidemia is compounded by emergent fluconazole- and voriconazole-resistant
non-Candida strains [9]. The bis-oxazole natural products, bengazoles A (2a) and B (2b), also from
Jaspis cf. coriacea [10,11], and their homologs C–G (2c–g) from an Australian Jaspis sp. [12], are potent
antifungal agents (minimum inhibitory concentration, MIC, ~ 1 µg mL–1 [12]).
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Figure 1. Structures of bengamides and bengazoles.
The absolute stereochemistry of 1a was determined by measuring the NMR anisotropy of the S-
and R-mandelate esters of a related co-isolated lactone [10]. The absolute stereochemistry of 2a was
determined through comparisons of the CD spectra of the corresponding tetra p-bromobenzoate
esters and synthetic models of defined configuration [12]. The first total syntheses of 1a [13]
(which confirmed the absolute configuration) and 2a [14,15] were reported in 1992 and 1999,
respectively, followed by several other bengamide syntheses; only two other syntheses of bengazoles
have appeared [16,17]. The chemistry and the biology of bengamides and bengazoles were the subject
of a recent comprehensive review [18].
A limited structure–activity study suggested that the two oxazole rings are required in 2a–g for
potent antifungal activity [19], as is the long fatty acyl chain. The saponification product of bengazoles
A–G gave the pentaol 2h [10] which was devoid of activity [12]), but few other substitutions are
tolerated [19].
Bengamides—which co-occur with bengazoles in Jaspis sp.—lack antifungal activity against
C. albicans yet remarkably, the anti-Candida activity of crude and partially purified Jaspis sp. extracts
exceed the activity of purified bengazoles in the disk diffusion assay. For example, pure 2e (MIC = 1 µM
against C. albicans [12]) at 0.5 µg disk−1 induced a zone of inhibition of 9–10 mm against C. albicans, but
a solvent-partitioned fraction containing a mixture of homologous bengazoles and bengamides created
a zone of inhibition far larger (40 mm) at comparable loadings (unpublished results, see Figure S4).
This observation suggested synergism in the multi-component mixture that may involve bengazole
and bengamide interactions, or more complex activities that impaired fungal cell metabolism, leading
to cellular collapse.
The precise molecular mechanism of action (MOA) of the bengazoles has not been determined,
but we have shown that the antifungal activity of 2a was suppressed in the presence of exogenous
ergosterol (3) in a concentration-dependent manner [20], reminiscent of the MOA of polyene antifungal
agents (e.g., amphotericin B [21,22]). The structure of 2a bears some resemblance to clinically approved
drugs—the so-called ”azole” antifungal agents (e.g., fluconazole, 4, and clotrimazole, 5, Figure 2).
The latter embody two imidazole or pyrazole rings appended to a central carbinol, while 2 displays
two 1,3-oxazole rings arrayed around an esterified carbinol.
The structural similarities between antifungal azole drugs and 2 suggested that the two classes
of compound might manifest the same MOA: namely, inhibition of lanosterol 14α-demethylase
(We credit and thank Professor Yuzuru Shimizu (University of Rhode Island) for suggesting this
hypothesis). The proposal is made more plausible by observations of inhibition of the growth of fungi
by generic azoles as simple as imidazole itself [23], and the known mode of binding of azoles through
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coordination of the basic N to the Fe-heme core of 14α-demethylase [24]. Here, we report the results of
the investigations of the MOA of bengazole natural products, including the antifungal synergism of
bengazole A and bengamide A, and present the disproval of an azole-like suppression of ergosterol
biosynthesis for the MOA of the former.
Figure 2. Oxidative remodeling in the bioconversion of lanosterol (6) to ergosterol (3) (abbreviated).
Azole antifungal drugs, fluconazole (4) and clotrimazole (5), block lanosterol 14α-demethylase. Eburicol
(7) is a shunt metabolite.
2. Results
Bengazoles are the rare, less-abundant, and less-studied components in extracts of Jaspis sp.
Bengazoles are unstable: they are persistent in crude extracts, but upon purification, they undergo
spontaneous degradation through autoxidation of the oxazole ring over short timescales. Crews
et al. reported the co-isolation of compounds formed from the degradation of 2a; their structures
were expected products of photosensitized [4+2] additions of 1O2 to one of the 1,3-oxazole rings,
followed by Wasserman-type fragmentation [25,26]. Remarkably, our type-sample extract of Jaspis sp.
(90-026) collected from the Great Barrier Reef and stored in MeOH (–20 ◦C) for 25 years was found to
retain antifungal activity. Remarkably, bengazoles, within crude extracts and prior to separation from
other components, have much better stability and prolonged ”shelf life”. This useful phenomenon
may be possibly attributed to photoprotection by pigments or antioxidant congeneric components in
unrefined mixtures. Pure bengazole A (2a, 0.5 µg) gave a zone of inhibition of 9–10 mm [12]. The latter
observation suggested the presence of intact bengazoles. In contrast, the bulk of the specimen had
been extracted and purified to provide the major compounds, bengazoles A (2a) and B (2b), and minor
homologs, C–G (2c–g), all of which subsequently decomposed [12].
2.1. Extraction–Isolation of Bengamides–Bengazoles
A portion of the MeOH supernatant from the type sample was separated by progressive solvent
partition, and the CH2Cl2-soluble fraction was further purified by silica gel flash chromatography to
yield a fraction containing a mixture of bengazoles (2a–g). Final purification by reversed-phase HPLC
gave pure 2, identified by MS and 1H NMR and comparison with literature values [10]. Purified 2a
(4 µg), determined with precision by microcryoprobe 1H NMR and quantitation using solvent 13C
satellites (QSCS) [27,28], provided sufficient sample for limited quantitative antifungal assays.
Ergosterol, the major sterol found in yeasts and other fungi, is a critical structural component
that maintains the integrity of cellular membranes. Amphotericin B and related polyene antifungal
agents exert their action by binding to ergosterol and inducing the formation of membrane pores
that are permeable to K+ ions and other small-molecular-weight metabolites [29]. A common target
exploited in the design of synthetic antifungal azoles is the inhibition of ergosterol biosynthesis [30],
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although recent efforts have been aimed at chitin-synthetase inhibitors [31]. Antifungal azoles inhibit
the 14α-demethylase, an enzyme that is critical for oxidative remodeling of the common triterpene
precursor lanosterol (6) (Figure 2) during ergosterol biosynthesis [32]. Although the structure of 2 is
reminiscent of antifungal azoles, the ergosterol-dependent activity of the former suggests that the
natural product targets ergosterol-lipid structured membranes by the formation of pores [21,29,30],
although the possibility of a dual mode of action for 2 cannot be excluded. In order to test the latter
hypothesis, the sterol composition of cultured C. albicans was monitored over time in the presence and
absence of drugs that are known disruptors of ergosterol biosynthesis.
2.2. Sterol Composition in C. albicans Co-Cultured with Azoles
Cultures of C. albicans ATCC 14503 were treated with the serially diluted bengazoles, and
incubated overnight at 35 ◦C. The crude broths were centrifuged and growth inhibition was estimated
on the basis of the cellular wet-weight of the pellets compared to the untreated control. Whole pellets
were saponified (40% KOH in EtOH-H2O, 2 h, 95 ◦C), and the non-saponifiable fractions were recovered
by extraction with ether, persilylated (N-(trimethylsilyl)imidazole), and the sterol composition was
determined by GCMS (Figure 3) of the corresponding O-TMS ethers of ergosterol, lanosterol, and
24-methylenedihydrolanosterol (3a, 6a, and 7a, respectively, see Supporting Information). Growth
inhibition was observed in the presence of 2, but there was no change in the concentrations of 3 relative
to the control (Figure 3b). To validate the method, azole 5 was tested under the same conditions.
A clear decrease in 3 (Figure 3c) was seen along with the appearance of a new peak due to the O-TMS
ether 7a of the expected shunt metabolite, 24-methylenedihydrolanosterol (eburicol, 7) [33,34].
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Figure 3. GCMS traces of O-TMS Sterols from C. albicans ATCC 14503 after co-incubation in the
presence and absence of 2 and 5. (A) C. albicans and media only. (B) C. albicans and 2. (C) C. albicans and
5. Key: O-TMS ergosterol (3a), m/z 468, 378, 363, 337; O-TMS lanosterol (6a), m/z 498, 483, 393; O-TMS
24-methylenedihydrolanosterol (O-TMS eburicol, 7a), m/z 512, 497, 407. For complete GCMS spectra,
see Supporting Information.
2.3. Synergistic Antifungal Activity of Bengazole–Bengamide Mixtures
In order to investigate possible antifungal synergism, mixtures of bengazoles A–G (2a–g; hereafter
referred to as 2 for brevity), at a constant loading (0.5 µg disk−1), and variable amounts of bengamide
A (1a), were combined and tested in a disk diffusion assay (Figure 4). Surprisingly, at 200 µg disk−1 of
1a (400:1 mass ratio of 1a:2), complete inhibition of the antifungal activity of 2 was observed. When
the relative concentration of 1a was lowered, an unusual dose-dependent response was observed
(Figure 4); 1a inhibited antifungal activity of 2 at 15 µg disk−1 (30:1 ratio), but increased the zone of
inhibition (~50%) at 1 µg of 2 (2:1 ratio of 1a to 2).
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Figure 4. Antifungal disk diffusion assay a of bengazole b–bengamide mixtures b a. a A lawn of
Candida albicans ATCC 14503 was spread onto Muller-Hinton (M-H) agar plates. Bengazoles (2, 0.5 µg
disk−1) and bengamide A (1, variable loadings) were applied as solutions to the same 6 mm paper
disk. The disks were dried, placed on M-H media agar plates, and incubated overnight at 35 ◦C.
The diameter of the zone of inhibition was recorded (± 0.5 mm); b Under these conditions, bengazoles
(2) alone (0.5 µg disk−1) gave a 10 mm zone of inhibition.
Further reductions in the ratio of 1a to 2 showed no changes compared to the control. In contrast,
the microbroth dilution assay using checkerboard [35] permutations of concentrations of 1a and 2
did not reproduce the synergism observed with disk diffusion assays. As noted earlier, bengazoles
are unstable. The time-dependent decomposition of 2 under the more prolonged incubation in the
microbroth dilution assay or disk diffusion-related phenomena may account for the different responses
under the two assay regimes.
3. Discussion
Analysis of saponified cultures of C. albicans treated with clotrimazole (5) showed the appearance
of eburicol (7)—a shunt metabolite sterol biosynthesis as expected—whereas cultures treated with
bengazoles (2) did not. This implies that bengazole does not inhibit ergosterol biosynthesis in the
same manner as 3 and other azole antifungal drugs which inhibit 14α-demethylase. In the latter
case, the relatively higher ratio of lanosterol (6) to ergosterol (3) may suggest a buildup of the
former—implying there is an inhibition of biosynthesis at an earlier stage—but absence of an internal
standard limited conclusions on a more quantitative basis. We cannot exclude the inhibition of the
biosynthesis of 3 by 2 at other steps in sterol biosynthesis (e.g., inhibition of squalene epoxidase [36,37]),
however, testing this hypothesis will require an expanded, more quantitative experimental design.
Synergistic activity in antibiotics is not uncommon [38,39], but is less-frequently reported for
antifungal drugs [40]. We, and others, have noted synergism in antifungal microbroth dilution
assays (MICs) of antifungal cyclic peptides, e.g. lobocyclamides from the cyanobacterium Lyngbya
majuscula [41]. Moore and coworkers noted similar behavior in disk diffusion assays with the
related peptides, laxaphycins A and B from the cyanobacterium Hormothamnion enteromorphoides
(see Refs. [42,43] (interestingly, synergism was also observed for combinations of new laxaphycins in
antiproliferative assays of cultured HCT-116 colon cancer cells [44]). Whether the synergistic fungal
inhibition observed under microbroth dilution assays can be translated into improved efficacy in
animal models of disseminated mycoses is a matter worthy of further study.
It is worth commenting that many studies of naturally occurring marine products with antifungal
properties [45], although reports of significant in vitro activity against cultured fungi, have lacked
experimental proof that might illuminate details of MOA. These shortfalls may have side-lined
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potentially new mechanistic insights; yet speculative hypotheses abound. For example, the well-known
antifungal activity of long-chain ”two-headed” aminoalkanols (e.g., oceanapiside [46]) found in
sponges of the genera Oceanapia, Rhizochalina, Leucetta, and Calyx [47] were thought to exert antifungal
activity by mimicking intermediates in the biosynthesis of sphingolipids and related long-chain
bases [48], but evidence has mounted to support alternative models of the inhibition of fungal cell
growth through actin-binding and the disruption of microfilaments [49]. Clearly, early identification of
MOA is an asset in identifying viable leads from ”hits” in antifungal drug discovery campaigns.
Studies of antibiosis against bacteria that follow canonical MOAs are familiar (e.g., penicillins:
inhibition of cell-wall biosynthesis; erythromycin: disruption of protein translation at rRNA [21]).
In contrast, the characterization of antifungal MOAs has presented inordinately encumbered challenges,
complicated by diploid pathogenic organisms that exhibit fewer genetic and metabolic differences
from the host organism compared to bacteria. In the future, well-designed in vitro experiments that
link read-outs of antifungal phenotypes with specific MOAs will be more desirable in screening-based
discovery programs for natural products.
4. Materials and Methods
4.1. General Experimental Procedures
Inverse detected 2D NMR spectra were measured on a ECA (500 MHz) NMR spectrometer
(Jeol, Peabody, MA, USA), equipped with a 5 mm 1H-{13C} probe, or an Avance III (600 MHz)
NMR spectrometer (Bruker, Billerica, MA, USA), fitted with a 1.7 mm 1H-{13C} microcryoprobe.
High-resolution ESITOF analyses were carried out on an Agilent 1200 HPLC coupled to an Agilent 6230
TOFMS (Agilent, Santa Clara, CA, USA), calibrated immediately before measurement against an ESL-L
low concentration tuning mix (part number G1969-85000, Agilent Technologies). Low-resolution MS
measurements were made on a Thermoelectron Surveyor UHPLC (Thermo Fisher, Waltham, MA,
USA) coupled to an MSD single-quadrupole detector. HPLC was performed on an Agilent 1200 HPLC.
Other General Experimental details can be found elsewhere [50].
4.2. Extraction and Purification of Bengazole A
An aliquot (5 mL) of the supernatant from Jaspis sp. (type sample 90-20-026), stored in MeOH
(10 mL), was extracted with hexanes (5 mL × 2). Concentration of the hexane-soluble layer gave
fraction A. The aqueous-MeOH layer was adjusted to 2:3 H2O:MeOH and extracted with CH2Cl2
(7 mL × 2) to yield, after removal of volatiles, fraction B (3.3 mg). Fraction B was separated by silica gel
flash chromatography (stepped gradient, 2.5% MeOH increments in CH2Cl2 to 10:90 MeOH:CH2Cl2)
followed by a 50:50 MeOH:CH2Cl2 wash, to yield five fractions (monitored by 1H NMR, 500 MHz).
Fractions 4 and 5 were combined and purified by reversed-phase HPLC (Phenomenex Luna C18
column, 250 × 4.6 mm, linear gradient; initial conditions 25:75 H2O:CH3CN to 100% CH3CN over 17
min, 1 mL min–1 flow rate, UV 217 nm, and ELSD detection) to yield compound 2a (4 µg, tR = 11.8 min).
The amount of 2 was quantitated by the solvent 13C-satellites (QSCS) method [28] using a 1H NMR
microcryoprobe (600 MHz, CDCl3).
4.3. Quantification of Ergosterol from C. albicans ATCC 14503
A two-fold dilution series was prepared from Sabouraud-dextrose broth (SabDex, 2 mL) in each
of 8 × 25 cm2 flasks. Overnight liquid cultures (10 µL) of C. albicans ATCC 14503 were added and
incubated at 35 ◦C overnight with gentle shaking. The culture broths were centrifuged, washed
(2 × PBS), and the wet pellet was weighed to estimated growth inhibition. The control pellet and
one with 50% growth inhibition were saponified in 40% KOH solution (8:1 EtOH:water, 500 µL) at
95 ◦C for 2 h. The non-saponifiable material was diluted with deionized H2O (2 mL) and vigorously
extracted with diethyl ether (2×, vortex 30 s, followed by centrifugation, 5 min). The combined organic
layers were dried under a stream of N2 and the residue dissolved in n-hexane (500 µL), then treated
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with N-(trimethylsilyl)imidazole (10 µL, Pierce). Samples were analyzed by GCMS (1 µL injection,
1.2 mL min–1 He, 70 ◦C for 2 min, ramp to 270 ◦C over 24 min, ramp to 300 ◦C at 35 min, EI detection).
Sterols were identified (see Figure 3 and Supporting Information, S1–S3) by comparisons of peak m/z
values, including fragmentation patterns, against entries from the NIST MS data library. Extracts of
C. albicans liquid cultures, grown in the presence of growth inhibitory concentrations (50% reduction
of cellular mass) of bengazole A or clotrimazole, were also analyzed by GCMS and compared with
control cultures (see Figure 3).
4.4. Antifungal Disk Diffusion Assay
An overnight liquid culture of C. albicans ATCC 14503 was diluted 100-fold and spread on
Mueller-Hinton agar plates. Aliquots of each compound were applied as solutions in MeOH onto
sterile paper disks (6.0 mm). After five minutes, the disks were placed on the yeast-coated agar plates,
and incubated overnight (~16 h) at 35 ◦C. Antifungal activity was estimated by the measurement of
zones of inhibition (>6.0 mm ± 0.5 mm, Figure 4).
5. Conclusions
We reported the potential synergistic activity of bengamide A (1) and bengazoles. Remarkably,
a 25-year old sample of Jaspis sp. collected from the Great Barrier Reef, Australia, retained potent
antifungal activity, which guided the separation of 1 from 2 using an agar-based disk diffusion assay.
Re-assay of the pure compounds confirmed that 1 was devoid of antifungal activity against Candida
albicans, but mixtures of 1 and 2 displayed synergistic activity with optimum enhancement of the
zone of inhibition at a ratio of 2:1. Although inhibition of fungal growth was observed in cultures of
C. albicans in the presence of 2, no suppression of ergosterol biosynthesis was detected, suggesting
a MOA that differs from 14α-demethylase inhibition, common to the azole antifungal drugs. Further
investigations into the MOA of potent antifungal bengazoles are in progress.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/17/2/102/s1.
LCMS data of sterol O-TMS ethers and first record of ”synergism”.
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